The distribution and location of mutations were comparable between AML-MRC and AML-RUNX1m, as had been already published [19] RUNX1 mutations co-occurred with other MR-mutations in a high percentage of cases, and specifically with BCOR/BCORL1 mutations, considerably reducing the impact of the different consideration of this gene in new classifications. This evidence concerns the gene RUNX1 and acute myeloid leukemia.